000			02169pam a2200313 a 4500
005			20250914164042.0
008			080327s2008 njua b 001 0 eng
020			_a9780471794417 (cloth) _cRM259.04
020			_a0471794414 (cloth)
039		9	_a200804291216 _bruzini _c200804291216 _druzini _y03-27-2008 _zfida
040			_aUKM
060			_aQV38 _b.D7916 2008 9
090			_aQV38.D7916 2008 9
245	0	0	_aDrug-drug interactions in pharmaceutical development / _cedited by Albert P. Li
260			_aHoboken, N.J. : _bWiley-Interscience, _cc2008
300			_axiv, 244 p. : _bill. ; _c24 cm.
440		0	_aWiley series in drug discovery and development
504			_aIncludes bibliographical references and index
505	0		_aIn vitro evaluation of metabolic drug-drug interactions: concepts and practice / Albert P. Li -- In vitro approaches to anticipating clinical drug interactions / Laurie P. Volak, David J. Greenblatt, and and Lisa L. von Moltke -- Inhibition of drug-metabolizing enzymes and drug-drug interactions in drug discovery and development / R. Scott Obach -- Mechanism-based CYP inhibition: enzyme kinetics, assays, and prediction of human drug-drug interactions / Magang Shou -- Genomic approaches to drug-drug interactions / Yi Yang and Jeffrey F. Waring -- Transporters and drug interactions / Yoshihisa Shitara, Toshiharu Horie, and Yuichi Sugiyama -- Transporter-mediated drug interactions: molecular mechanisms and clinical implications / Jiunn H. Lin -- Recent case studies of clinically significant drug-drug interactions and the limits of in vitro prediction methodology / Rene H. Levy, Isabelle Ragueneau-Majlessi, Carol Collins -- U.S. regulatory perspective: drug-drug interactions / John Strong and Shiew-Mei Huang -- Herbal drug interactions: a Canadian perspective / Brian C. Foster
650		2	_aDrug interactions
650		2	_aChemistry, Pharmaceutical
700	1		_aLi, A. P.
907			_a.b14093327 _b2019-11-12 _c2019-11-12
942			_c01 _n0 _kQV38.D7916 2008 9
914			_avtls003366667
991			_aJabatan Farmakologi, KKL
998			_ad _b2008-01-03 _cm _da _feng _gnju _y0 _z.b14093327
999			_c405370 _d405370